1 active not recruiting, 1 completed, 1 unknown. 2 Phase 2, 1 Phase 1.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 2 | Active not recruiting 1, Unknown 1 |
| Phase 1 | 1 | Completed 1 |
Follow MitoImmune Therapeutics: new trials by email
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Clinical Trial to Evaluate Pharmacokinetic Characteristics of MIT-001 After SC Administration in Healthy Subjects Single subcutaneous administration and Blood collection, Single subcutaneous administration and then IV injection., MIT-001 20mg and 40mg_Multiple administration - Heathly Subjects | Phase 1 | Completed | MitoImmune Therapeutics | 40 | 2022-05-13 | 2023-08-24 |
| Evaluate the Safety and Efficacy for Oral Mucositis Prevention of MIT-001 in Auto HSCT MIT-001, normal saline - Oral Mucositis, Lymphoma | Phase 2 | Unknown | MitoImmune Therapeutics | 60 | 2022-02-01 | 2024-05-29 |
| MIT-001 for Prevention of CCRT-Induced OM in HNSCC Patients MIT-001 plus CCRT - Head and Neck Squamous Cell Carcinoma, Oral Mucositis | Phase 2 | Active not recruiting | MitoImmune Therapeutics | 60 | 2021-06-21 | 2025-04-06 |
Stomatitis (2) · Hematologic Neoplasms (1) · Lymphoma (1) · Multiple Myeloma (1) · Squamous Cell Carcinoma of Head and Neck (1)
Saline Solution (1)
South Korea (3) · United States (1)
Jinsang Jung, M.Pharm (1) · Seok-Goo Cho, MD, PhD (1) · SeungHwan Lee, MD (1)